COVID-19 Research

Vanderbilt University Medical Center researchers, supported by the National Institutes of Health (NIH), are leading a nationwide clinical trial to explore the safety and effectiveness of a group of novel drugs designed to protect patients hospitalized with COVID-19 at high risk of poor outcomes. The new trial has enrolled its first patient.

The Vanderbilt Institute for Clinical and Translational Research (VICTR) has been awarded a major federal grant to lead a national trial of treatments targeting the Renin Angiotensin Aldosterone System (RAAS) in patients hospitalized with COVID-19.

Vanderbilt University Medical Center (VUMC) has been named Data Coordinating Center (DCC) for a nationwide platform of studies aimed at “repurposing” existing drugs to treat mild to moderate symptoms of COVID-19.

Dr. Wilkins testified before the U.S. Senate Health, Education, Labor & Pensions Committee on Examining Our COVID-19 Response: Improving Health Equity and Outcomes by Addressing Health Disparities. It was exciting to hear her reference several of our projects and to witness the impact of our combined efforts and contributions are making on a national level!

Statewide stay-at-home orders put in place as Tennessee fought to control the spread of coronavirus last March were associated with a 14% lower rate of preterm birth, according to a research letter published today in JAMA Pediatrics. Preterm infants have higher morbidity and mortality risks than babies born at term.

NASHVILLE, Tenn. (WTVF) — In a lot of cases, securing a COVID-19 vaccination appointment is like winning the golden ticket. However, for some, the vaccination relief is followed by guilt after getting the shot. "They can feel a little guilty, that’s okay, in time as they realize that they are now insulated to a large degree against a very nasty situation that is developing COVID-19," Dr. Jim Jackson said, "They’re going to feel good, and in time their loved ones are going to get the vaccine."

As the Food and Drug Administration (FDA) has approved adding a third COVID-19 vaccine to the rollout, a multicenter study led by Vanderbilt University Medical Center will evaluate how effective the vaccines are in preventing hospitalization from COVID-19. In 2020, clinical trial data showed that the current SARS-CoV-2 vaccines were effective at preventing infections and severe illness from COVID-19 in the clinical trial setting.

Vanderbilt’s data-driven, systems approach aims for meaningful change.

HERO-TOGETHER is an opportunity for people working in health care who receive a COVID-19 vaccine to help the public understand how people do after vaccination. The COVID-19 pandemic is a once-in-a-generation challenge that health care heroes everywhere have worked together to face. From working on the front lines to working behind the scenes, people in healthcare and public service have joined together with unprecedented focus to fight COVID-19.